Intravenous Iron Supplement for Iron Deficiency in Cardiac Transplant Recipients (IronIC) - A Randomized, Double Blind, Controlled Trial
| Autor: | Arne K. Andreassen, T. Vartdal, Lars Gullestad, C.M. Østby, Kaspar Broch, Katrine Rolid, K.V. Brautaset Englund, Einar Gude |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Pulmonary and Respiratory Medicine
Transplantation medicine.medical_specialty business.industry Intravenous iron Iron deficiency medicine.disease Graft function law.invention Double blind Randomized controlled trial Tolerability Quality of life law Internal medicine Medicine Surgery Cardiology and Cardiovascular Medicine business Iron therapy |
| Zdroj: | The Journal of Heart and Lung Transplantation. 39:S144 |
| ISSN: | 1053-2498 |
| DOI: | 10.1016/j.healun.2020.01.1067 |
| Popis: | Summary of Objectives Heart transplant recipients have reduced exercise capacity despite preserved graft function. Numerous mechanisms may contribute to this impaired exercise tolerance, one of which may be iron deficiency (ID). Among our heart transplant survivors, 48 % have ID. The IronIC trial (NCT03662789) was designed to test the hypothesis that intravenous (i.v.) iron therapy will improve exercise capacity assessed by peak oxygen consumption. Methods 102 stable, cardiac transplant recipients with ID, defined as serum ferritin Endpoints The primary objective is to assess baseline-adjusted peak oxygen consumption, six months after one single dose of iron isomaltoside. Secondary objectives are to assess the impact of treatment on iron stores, muscle strength, cognitive function, quality of life, safety and tolerability. This study will give insight to whether heart transplant recipients with ID can benefit from intravenous iron supplement. Results will be ready for presentation at the 2020 ISHLT conference. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|